GLA and Fabry disease: In an analysis of FOS registry data (mean treatment duration: ~11 years), male patients with classic FD who started agalsidase alfa treatment before 25 years of age (n = 32) had a nonsignificant mean (standard error [SE]) annual increase in LVMI of 0.28 (0.30) g/m2.7, whereas those who started treatment at or after 25 years of age (n = 58) had a significant mean (SE) annual LVMI increase of 1.03 (0.21) g/m2.7 (p < 0.0001) [41].